Newbury Pharmaceuticals AB (ST:NEWBRY) — Market Cap & Net Worth
Market Cap & Net Worth: Newbury Pharmaceuticals AB (NEWBRY)
Newbury Pharmaceuticals AB (ST:NEWBRY) has a market capitalization of $6.28 Million (Skr58.36 Million) as of June 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #28110 globally and #627 in its home market, demonstrating a 13.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Newbury Pharmaceuticals AB's stock price Skr1.92 by its total outstanding shares 30397889 (30.40 Million). Review NEWBRY total liabilities to assess the company's total debt and financial obligations.
Newbury Pharmaceuticals AB Market Cap History: 2022 to 2026
Newbury Pharmaceuticals AB's market capitalization history from 2022 to 2026. Data shows change from $22.87 Million to $6.28 Million (-34.98% CAGR).
Index Memberships
Newbury Pharmaceuticals AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.84 Billion | 0.04% | #185 of 281 |
Weight: Newbury Pharmaceuticals AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Newbury Pharmaceuticals AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Newbury Pharmaceuticals AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.31x
Newbury Pharmaceuticals AB's market cap is 0.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $22.87 Million | $5.52 Million | -$14.67 Million | 4.15x | N/A |
| 2023 | $10.04 Million | $10.27 Million | -$19.43 Million | 0.98x | N/A |
| 2024 | $11.51 Million | $36.83 Million | -$15.40 Million | 0.31x | N/A |
Competitor Companies of NEWBRY by Market Capitalization
Companies near Newbury Pharmaceuticals AB in the global market cap rankings as of June 19, 2026.
Key companies related to Newbury Pharmaceuticals AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Newbury Pharmaceuticals AB Historical Marketcap From 2022 to 2026
Between 2022 and today, Newbury Pharmaceuticals AB's market cap moved from $22.87 Million to $ 6.28 Million, with a yearly change of -34.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr6.28 Million | +66.96% |
| 2025 | Skr3.76 Million | -67.33% |
| 2024 | Skr11.51 Million | +14.66% |
| 2023 | Skr10.04 Million | -56.08% |
| 2022 | Skr22.87 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Newbury Pharmaceuticals AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.28 Million USD |
| MoneyControl | $6.28 Million USD |
| MarketWatch | $6.28 Million USD |
| marketcap.company | $6.28 Million USD |
| Reuters | $6.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Newbury Pharmaceuticals AB
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.